MHC class II restricted neoantigen: A promising target in tumor immunotherapy. (28th April 2017)

• Record Type: Journal Article
• Authors: Sun, Zhichen; Chen, Fangjun; Meng, Fanyan; Wei, Jia; Liu, Baorui
• Is Part Of: Cancer letters. Volume 392(2017)
• Page Start: 17
• Page End: 25
• Publication Date: 2017-04-28
• Subjects: MHC class II restricted neoantigen -- CD4+ T cell -- Tumor vaccine -- Adoptive cell transfer -- TCR-T cell -- Tumor immunotherapy; mAb monoclonal antibody -- BiTE bispecific T cell engager -- ACT adoptive cell transfer -- TAs tumor antigens -- CTA cancer-testis Ag -- TILs tumor-infiltrating lymphocytes -- CTL cytotoxic T cell -- IL-2 interleukin 2 -- CD40L CD40 ligand -- ROS reactive oxygen species -- GTE genetic targeting expression system -- WES whole-exome sequencing -- TMG tandem minigene -- IVT in vitro transcribed -- CTCs circulating tumor cells -- ERBB2IP erbb2 interacting protein -- IDH1 isocitrate dehydrogenase type 1 -- MERIT mutanome engineered RNA immunotherapy -- PR partial regression -- TCR-T cell T-cell receptor T cell -- CAR-T cell chimeric antigen receptor T cell -- EMT epithelial–mesenchymal transition; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2016.12.039
• Languages: English
• ISSNs: 0304-3835

Abstract

Abstract: Neoantigen is a patient-specific tumor antigen resulted from mutations during oncogenesis. Emerging data suggested that immune responsiveness against neoantigens correlated with the success of clinical tumor immunotherapies. Nowadays, the majority of studies on neoantigens have focused on MHC class I restricted antigens recognized by CD8+ T cells. With improved understanding of the underlying principles of tumor biology and immunology, increasing emphasis has been put on CD4+ T cells and MHC class II restricted antigens. MHC class II restricted neoantigen has the potential to be a promising target of tumor immunotherapy, although the limited comprehension and technical difficulties need to be overcome before being applied into clinical practice. This review discussed the immunologic mechanism, screening technique, clinical application, limitations and prospectives of MHC class II restricted neoantigens in tumor immunotherapy. Highlights: The role of CD4+ T cells in antitumor immunity. MHC class II restricted neoantigens show advantages in tumor immunotherapy. Screening methods for MHC II restricted neoantigens. The application of MHC class II restricted neoantigens in tumor immunotherapy. The limitations and perspectives of MHC class II restricted neoantigens.